feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

trending

Islamabad suicide blast kills 31

trending

Ronaldo trains with Al Nassr

trending

India A vs Namibia live

trending

Vaibhav Suryavanshi scores 175

trending

VTU adopts Artificial Super Intelligence

trending

Riyan Parag scores fifty

trending

T20 World Cup opening ceremony

trending

Tiigers Kolkata reach ISPL final

trending

Al Ettifaq favored vs Damac

Home / Health / Muscle Metabolism Drug Offers Weight Loss Hope

Muscle Metabolism Drug Offers Weight Loss Hope

8 Dec, 2025

Summary

  • New compound boosts metabolism directly in muscles, not hunger pathways.
  • Animal studies showed improved blood sugar and body composition.
  • Human trials suggest the treatment is well-tolerated, with no muscle loss.
Muscle Metabolism Drug Offers Weight Loss Hope

A novel compound has been developed, showing promise in enhancing metabolic activity directly within muscles and improving blood sugar levels. This new drug operates differently from widely-used GLP-1 medications like Ozempic and Wegovy, which primarily affect hunger pathways through gut-brain communication. The research indicates this new compound could offer a weight-loss solution without the typical side effects associated with GLP-1 injections, such as decreased appetite and muscle mass.

Previous experiments in animals demonstrated that the compound effectively improved blood sugar regulation and body composition. Recent studies involving human volunteers, including those with type 2 diabetes, suggest the treatment is well-tolerated. Researchers highlight the importance of muscle mass for overall health and life expectancy, positioning this drug as a significant advancement.

This innovative drug acts on smooth muscle receptors throughout the body, promoting muscle function without overstimulating the heart. It represents a distinct therapeutic approach that can be used independently or in conjunction with GLP-1 medications. Future trials are planned to further investigate its effects on individuals with type 2 diabetes and obesity.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Researchers from Stockholm University have developed a new compound that boosts muscle metabolism and improves blood sugar levels, potentially aiding weight loss without the side effects of GLP-1 drugs.
Unlike Ozempic, which acts on hunger pathways, the new drug boosts metabolic activity directly within muscles, avoiding common side effects like appetite loss and muscle mass reduction.
Early human studies involving healthy volunteers and individuals with type 2 diabetes suggest the new compound is well-tolerated and safe.

Read more news on

Healthside-arrow
•

You may also like

Wegovy Pill Ends 'Food Noise' for Mom

4 Feb • 10 reads

article image

Supermarkets Cash In on Weight-Loss Drug Trend

17 Jan • 111 reads

article image

Ozempic Patents Expire: Generics Set to Slash Drug Costs Globally

15 Jan • 207 reads

article image

Amgen's Obesity Drug Shows Weight Loss Maintenance

13 Jan • 153 reads

article image

Novo Nordisk: Oral GLP-1s to dominate market

13 Jan • 132 reads

article image